"We continue to make good progress with our Phase 3 asthma and migraine
programs and look forward to reporting data from both programs during the
first half of 2009," said
UDB Phase 3 Program
The initial UDB Phase 3 clinical trial completed enrollment in
UDB is being studied as a novel version of nebulized budesonide. Budesonide has been used clinically for more than 20 years. UDB is designed to be nebulized more quickly and at a lower nominal dose than the commercially available product. The safety data generated to date has shown UDB to be well tolerated with no significant adverse events reported.
MAP0004 Phase 3 Program
MAP Pharmaceuticals expects to complete enrollment in its initial Phase 3
clinical trial for the acute treatment of migraine by the end of
MAP0004 is a novel, orally inhaled migraine medication in development which has a multi-targeted mechanism of action, utilizes the company's proprietary TEMPO(R) inhaler and is designed to optimize the key characteristics of dihydroergotamine, an active ingredient which has been used to effectively and safely treat migraine for over 60 years. MAP0004 has the potential to provide a faster onset of action than currently available migraine treatments, with sustained pain relief and pain freedom, in an easy- to-use, non-invasive, at-home therapy. In a Phase 2 clinical trial, patients reported pain relief in as fast as 10 minutes with sustained relief to 48 hours. The safety data generated to date have shown MAP0004 to be well tolerated with no significant adverse events reported.
About MAP Pharmaceuticals, Inc.
MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and history.
Forward Looking Statements
In addition to statements of historical facts or statements of current
conditions, this press release contains forward-looking statements, including
with respect to MAP Pharmaceuticals' late stage clinical programs. Actual
results may differ materially from current expectations based on risks and
uncertainties affecting MAP Pharmaceuticals' business, including, without
limitation, risks and uncertainties relating to the failure to obtain
clearance of the collaboration agreement with AstraZeneca under the
Hart-Scott-Rodino Act, the enrollment, conduct, completion and reporting of
clinical trials, as well as risks related to the failure to achieve favorable
clinical outcomes or to have the company's product candidates approved for
commercial use by the U.S. Food and Drug Administration. The reader is
cautioned not to unduly rely on the forward-looking statements contained in
this press release. MAP Pharmaceuticals expressly disclaims any intent or
obligation to update these forward-looking statements, except as required by
law. Additional information on potential factors that could affect MAP
Pharmaceuticals results and other risks and uncertainties are detailed in its
Quarterly Report on Form 10-Q, filed with the SEC on
SOURCE MAP Pharmaceuticals, Inc.